Page last updated: 2024-11-01

omeprazole and Cholera Infantum

omeprazole has been researched along with Cholera Infantum in 98 studies

Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.

Research Excerpts

ExcerptRelevanceReference
"Our purpose was to determine whether omeprazole use during pregnancy is associated with an increased risk of malformations, spontaneous abortions, decreased birth weight, or perinatal complications."9.08The safety of omeprazole during pregnancy: a multicenter prospective controlled study. ( Addis, A; Bonati, M; Koren, G; Lalkin, A; Loebstein, R; Mastroiacovo, P; Mazzone, T; Ramezani-Namin, F; Vial, T, 1998)
"Aspirin is indicated for primary and secondary prevention of cardiovascular diseases (CVD) by major guidelines."8.95Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. ( Bliden, K; Chaudhary, R; Gurbel, PA; Sharma, T; Tantry, U, 2017)
"Lafutidine could offer the possibility of more effective prevention of CT-induced mucositis through the activation of GI mucus cells."7.74Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. ( Goso, Y; Ichikawa, T; Ikezawa, T; Ishihara, K; Iwai, T; Nakano, M; Saegusa, Y; Saigenji, K; Shikama, N, 2008)
"GI symptoms in children with cystinosis receiving cysteamine are often acid-mediated and improve with omeprazole."7.72The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. ( Deutsch, R; Dohil, R; Newbury, RO; Schneider, JA; Sellers, ZM, 2003)
" pylori-positive peptic ulcer received lansoprazole 30 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 250 mg twice daily for 5 days."5.08Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? ( Cunnane, K; Kelly, S; Laundon, J; McLoughlin, R; O'Connor, HJ, 1998)
"Our purpose was to determine whether omeprazole use during pregnancy is associated with an increased risk of malformations, spontaneous abortions, decreased birth weight, or perinatal complications."5.08The safety of omeprazole during pregnancy: a multicenter prospective controlled study. ( Addis, A; Bonati, M; Koren, G; Lalkin, A; Loebstein, R; Mastroiacovo, P; Mazzone, T; Ramezani-Namin, F; Vial, T, 1998)
"Aspirin is indicated for primary and secondary prevention of cardiovascular diseases (CVD) by major guidelines."4.95Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. ( Bliden, K; Chaudhary, R; Gurbel, PA; Sharma, T; Tantry, U, 2017)
" We report 3 cases of anaphylactic reactions induced by lansoprazole or ranitidine diagnosed in a population of 8304 first-referral patients over a 13-year period."4.83Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature. ( Bozkurt, B; Demirkan, K; Kalyoncu, AF; Karakaya, G, 2006)
" pylori infection, a new one-week triple therapy regimen (lansoprazole or omeprazole + amoxicillin + clarithromycin) has been approved for use in patients with peptic ulcer disease in Japan."4.82Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. ( Hoshino, Y; Ishii, H; Kurabayashi, K; Masaoka, T; Minegishi, Y; Nomura, S; Suzuki, H; Suzuki, M, 2003)
"Perhaps older drugs to treat ulcers, such as antacids, are just as effective as the newer drugs, but veterinarians have all but abandoned these drugs in favor of H2-receptor antagonists, sucralfate, and omeprazole."4.78Antiulcer therapy. ( Papich, MG, 1993)
"Lafutidine could offer the possibility of more effective prevention of CT-induced mucositis through the activation of GI mucus cells."3.74Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. ( Goso, Y; Ichikawa, T; Ikezawa, T; Ishihara, K; Iwai, T; Nakano, M; Saegusa, Y; Saigenji, K; Shikama, N, 2008)
"GI symptoms in children with cystinosis receiving cysteamine are often acid-mediated and improve with omeprazole."3.72The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. ( Deutsch, R; Dohil, R; Newbury, RO; Schneider, JA; Sellers, ZM, 2003)
"To carry out a economic evaluation of diclofenac/misoprostol in the treatment of rheumatoid arthritis and osteoartritis when comparing with diclofenac alone, diclofenac + omeprazol, and diclofenac + ranitidine."3.70[Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases]. ( Soto Alvarez, J, 2000)
" Two 7-day treatments were separated by 14-day washout periods: (a) PA32540 + clopidogrel (300 mg loading/75 mg maintenance) 10 hours later and (b) synchronous dosing of clopidogrel + EC aspirin (81 mg) + EC omeprazole (40 mg)."2.78Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. ( Antonino, M; Bliden, KP; Chai, S; Fort, JG; Gesheff, M; Gesheff, T; Gurbel, PA; Jeong, YH; Shuldiner, A; Tantry, US; Zhang, Y, 2013)
"Pantoprazole was superior to misoprostol (p < 0."2.71Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. ( Dietrich, K; Fischer, R; González-Carro, P; Lühmann, R; Straszak, A; Stupnicki, T; Terjung, A; Thomas, KB, 2003)
"Ketoprofen monotherapy has been shown to be generally equivalent to other NSAIDs when used in the treatment of OA."2.48Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole. ( Gigante, A; Tagarro, I, 2012)
" As there are specific characteristics of these patients that could alter the pharmacokinetics of the drugs, studies need to be performed to determine the most suitable dose and dosage interval."2.46Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients. ( López-Herce, J; Solana, MJ, 2010)
"Esomeprazole has a good tolerability profile and a low potential for drug interaction."2.45The pharmacology of esomeprazole and its role in gastric acid related diseases. ( Saccar, CL, 2009)
" Protonic pump inhibitors (PPI) are considered to be the correct therapy in the treatment of peptic ulcers, as they have proven to be safe and efficient."2.44[Protonic pump inhibitors in kidney transplant patients: efficacy and safety]. ( Cianciolo, G; Comai, G; Feliciangeli, G; Stefoni, S, 2007)
"Gastric acid is pathogenic in many gastrointestinal disorders, such as gastroesophageal reflux disease and peptic ulcer disease."2.43Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. ( Robinson, M, 2005)
" Intravenous pantoprazole has been shown to maintain acid suppression in patients switched from oral PPIs, so no change in dosage is required when switching from one formulation to the other."2.41Switching between intravenous and oral pantoprazole. ( Pisegna, JR, 2001)
"Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion."2.40Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. ( Langtry, HD; Wilde, MI, 1997)
"The selection of agents to treat patients with acid-related gastrointestinal diseases requires knowledge of their efficacy, tolerability, and ease of dosing among individuals with differing disease severities and other baseline characteristics."2.40Review article: rabeprazole's profile in patients with gastrointestinal diseases. ( Barth, J; Humphries, TJ, 1999)
"Omeprazole remains a treatment of choice in patients with Zollinger-Ellison syndrome."2.39Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. ( McTavish, D; Wilde, MI, 1994)
"Renal failure has no influence on the pharmacokinetics of lansoprazole, but severe hepatic failure causes a significant decrease in clearance and an increase in the AUC and t1/2 of lansoprazole."2.39Clinical pharmacokinetics of lansoprazole. ( Flouvat, B; Landes, BD; Petite, JP, 1995)
" Moderate hypergastrinaemia occurs in some patients, especially if an omeprazole dosage of 40 mg/day is needed."2.39Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders. ( Creutzfeldt, W, 1994)
"Omeprazole is a powerful inhibitor of gastric acid secretion."2.38Omeprazole. Overview and opinion. ( Holt, S; Howden, CW, 1991)
" Reviewing the manner of administration and stated indications for use of both drugs, we find omeprazole is often administered outside dosing recommendations, and both drugs are frequently administered for aims that are unlikely to be achieved when considering their known biological effects in dogs."1.56Prospective observational study of the use of omeprazole and maropitant citrate in veterinary specialist care. ( Glanemann, B; McCormack, R; Olley, L; Swann, JW, 2020)
"Malnutrition and gastrointestinal disorders are very common in children with cerebral palsy."1.34Impact of malnutrition on gastrointestinal disorders and gross motor abilities in children with cerebral palsy. ( Campanozzi, A; Capano, G; Del Giudice, E; Miele, E; Militerni, R; Romano, A; Scuccimarra, G; Staiano, A; Strisciuglio, C, 2007)
"Treatment with omeprazole or melatonin prevented this damage as well as the changes in biochemical parameters, and melatonin appeared to be more efficient than omeprazole in protecting the mucosa."1.33Protective effect of melatonin and omeprazole against alendronat-induced gastric damage. ( Arbak, S; Dülger, GA; Ersoy, Y; Goren, FO; Sener, G; Ulusoy, NB, 2005)
" On logistic regression analysis, none of the confounding factors (sex, age, indication, chronic use of PPI, eradication protocol) were found to contribute to the discrimination between a negative (successful eradication) and a positive (failed eradication) 13CUBT."1.33Effectiveness of omeprazole- versus lansoprazole-based triple therapy for Helicobacter pylori eradication. ( Niv, Y, 2005)
"Fundic gland polyps have been described either in association with genetic polyposis syndromes of the colon, or in a sporadic form."1.33Sporadic fundic gland polyps: clinico-pathologic features and associated diseases. ( Bellone, S; Caruso, S; Declich, P; Ferrara, A; Tavani, E, 2005)
"The study involved a search of the Food and Drug Administration's database for adverse events and drug interactions with omeprazole, lansoprazole or pantoprazole as primary or secondary suspect drug."1.32A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. ( Koelz, HR; Labenz, J; Petersen, KU; Rösch, W, 2003)
"Esomeprazole was also effective in patients with symptomatic GORD."1.31Esomeprazole: a review of its use in the management of acid-related disorders in the US. ( Dunn, CJ; Mallarkey, G; Scott, LJ; Sharpe, M, 2002)
" The pharmacokinetic parameters of omeprazole were: systemic clearance, 0."1.29Pharmacokinetics of intravenous omeprazole in children. ( Andre, J; Baudouin, V; Bellaich, M; Faure, C; Jacqz-Aigrain, E; Navarro, J; Rohrlich, P, 1994)

Research

Studies (98)

TimeframeStudies, this research(%)All Research%
pre-19904 (4.08)18.7374
1990's28 (28.57)18.2507
2000's53 (54.08)29.6817
2010's12 (12.24)24.3611
2020's1 (1.02)2.80

Authors

AuthorsStudies
McCormack, R1
Olley, L1
Glanemann, B1
Swann, JW1
Andrade, PHS1
Lobo, IMF1
da Silva, WB1
García-Torres, I1
De la Mora-De la Mora, I1
Hernández-Alcántara, G1
Molina-Ortiz, D1
Caballero-Salazar, S1
Olivos-García, A1
Nava, G1
López-Velázquez, G1
Enríquez-Flores, S1
Kashour, T1
Al-Tannir, M1
Bahamid, R1
Asif, HM1
Zaidi, SF1
Sugiyama, T1
Akhtar, N1
Usmanghani, K1
Sharma, T1
Bliden, K1
Chaudhary, R1
Tantry, U1
Gurbel, PA2
Zhang, W1
Han, Y1
Fort, JG2
Schofield, D1
Tursi, JP1
Baranov, AA1
Shcherbakov, PL1
Saccar, CL1
Solana, MJ1
López-Herce, J1
Wagner, S1
Varet-Legros, MG1
Fabre, C1
Montastruc, JL1
Bagheri, H1
Yakoob, J1
Abid, S1
Abbas, Z1
Jafri, SN1
Gigante, A1
Tagarro, I1
Blackler, R1
Syer, S1
Bolla, M1
Ongini, E1
Wallace, JL1
Bliden, KP1
Jeong, YH1
Shuldiner, A1
Chai, S1
Gesheff, T1
Antonino, M1
Gesheff, M1
Zhang, Y1
Tantry, US1
Guda, N1
Vakil, N1
Sawhney, MS1
Nelson, DB1
Anagnostopoulos, GK1
Kostopoulos, P1
Margantinis, G1
Tsiakos, S1
Arvanitidis, D1
Labenz, J2
Petersen, KU1
Rösch, W1
Koelz, HR1
Pohland, CJ1
Scavnicky, SA1
Lasky, SS1
Good, CB1
Laheij, RJ2
Van Rossum, LG2
Jansen, JB2
Verheugt, FW2
Lanas, A1
Rodrigo, L1
Márquez, JL1
Bajador, E1
Pérez-Roldan, F1
Cabrol, J1
Quintero, E1
Montoro, M1
Gomollón, F1
Santolaria, S1
Lorente, S1
Cucala, M1
Nuevo, J1
Czuprynski, CJ1
Faith, NG1
Steinberg, H1
Neudeck, B1
Dohil, R1
Newbury, RO1
Sellers, ZM1
Deutsch, R1
Schneider, JA1
Yun, HR1
Bae, SC1
Suzuki, H2
Masaoka, T2
Nomura, S1
Hoshino, Y1
Kurabayashi, K1
Minegishi, Y1
Suzuki, M1
Ishii, H2
Takahashi, S1
Stupnicki, T1
Dietrich, K1
González-Carro, P1
Straszak, A1
Terjung, A2
Thomas, KB2
Lühmann, R2
Fischer, R2
Combe, B1
Flipo, RM1
Escalera Temprado, T1
Banzo Marraco, J1
Abós Olivares, MD1
Olave Rubio, MT1
Prats Rivera, E1
García López, F1
Razola Alba, P1
Maev, IV2
V'iuchnova, ES2
Staseva, IV1
Vlemmix, F1
Khatibi E, A1
Samsioe, G1
Li, C1
Lidfeldbt, J1
Agardh, CD1
Nerbrand, C1
Hata, M1
Shiono, M1
Sekino, H1
Furukawa, H1
Sezai, A1
Iida, M1
Yoshitake, I1
Hattori, T1
Wakui, S1
Soeda, M1
Taoka, M1
Negishi, N1
Sezai, Y1
Spiegel, BM1
Chiou, CF1
Ofman, JJ1
Niv, Y1
Robinson, M1
Sener, G1
Goren, FO1
Ulusoy, NB1
Ersoy, Y1
Arbak, S1
Dülger, GA1
Canbakan, B1
Mizrak, D1
Keven, K1
Kaygusuz, G1
Kutlay, S1
Sengul, S1
Erbay, B1
Sakai, G1
Hibi, T1
Horn, JR1
Howden, CW2
Declich, P1
Tavani, E1
Ferrara, A1
Caruso, S1
Bellone, S1
Konno, M1
Poncet, CM1
Dupre, GP1
Freiche, VG1
Bouvy, BM1
Demirkan, K1
Bozkurt, B1
Karakaya, G1
Kalyoncu, AF1
Ji, KY1
Hu, FL1
Regula, J1
Butruk, E1
Dekkers, CP1
de Boer, SY1
Raps, D1
Simon, L1
Campanozzi, A1
Capano, G1
Miele, E1
Romano, A1
Scuccimarra, G1
Del Giudice, E1
Strisciuglio, C1
Militerni, R1
Staiano, A1
Cahan, MA1
Balduf, L1
Colton, K1
Palacioz, B1
McCartney, W1
Farrell, TM1
Brewster, UC1
Perazella, MA1
Cianciolo, G1
Feliciangeli, G1
Comai, G1
Stefoni, S1
Chen, YF1
Jobanputra, P1
Barton, P1
Bryan, S1
Fry-Smith, A1
Harris, G1
Taylor, RS1
Saegusa, Y1
Ichikawa, T1
Iwai, T1
Goso, Y1
Ikezawa, T1
Nakano, M1
Shikama, N1
Saigenji, K1
Ishihara, K1
Dítĕ, P1
Prásek, J1
Wilde, MI2
McTavish, D2
Landes, BD1
Petite, JP1
Flouvat, B1
Jacqz-Aigrain, E1
Bellaich, M1
Faure, C1
Andre, J1
Rohrlich, P1
Baudouin, V1
Navarro, J1
Stolte, M1
Creutzfeldt, W1
Logan, RP1
Gummett, PA1
Misiewicz, JJ1
Karim, QN1
Walker, MM1
Baron, JH1
Papich, MG1
Jonkers, D1
Houben, P1
Stobberingh, E1
Stockbrügger, R1
Langtry, HD1
Schwartz, H1
Krause, R1
Siepman, N1
Haber, M1
Weissfeld, A1
Kidd, S1
Rose, P1
Sahba, B1
O'Connor, HJ1
McLoughlin, R1
Kelly, S1
Laundon, J1
Cunnane, K1
Bashford, JN1
Norwood, J1
Chapman, SR1
Lalkin, A1
Loebstein, R1
Addis, A1
Ramezani-Namin, F1
Mastroiacovo, P1
Mazzone, T1
Vial, T1
Bonati, M1
Koren, G1
Henry, A1
Batey, RG1
Unge, P1
Dajani, AI1
Awad, S1
Ukabam, S1
Nounou, MA1
Abdul Rasheed, Z1
Gautam, S1
Abdul Aal, G1
Nayal, S1
Pertusi, RM1
Godwin, KS1
House, JK1
Knebl, JA1
Alexander, JH1
Rubin, BR1
Forman, MD1
Savarino, V1
Neri, M1
Vigneri, S1
Evans, JS1
Huffman, S1
Humphries, TJ1
Barth, J1
Harewood, G1
Daudén, E1
Jiménez-Alonso, I1
García-Díez, A1
Horn, J1
Soto Alvarez, J1
Pilotto, A1
Franceschi, M1
Rassu, M1
Leandro, G1
Bozzola, L1
Furlan, F1
Di Mario, F1
De Francesco, V1
Stoppino, V1
Sgarro, C1
Faleo, D1
Garnett, WR1
Prescott, J1
Pisegna, JR1
Lebedev, EG1
Dicheva, DT1
Ovsiannikova, EV1
Antonenko, OM1
Shchekina, MI1
Bujanda, L1
Sánchez, A1
Iriondo, C1
Santos, A1
Cosme, A1
Muñoz, C1
McCarthy, DM1
Matheson, AJ1
Jarvis, B1
Scott, LJ1
Dunn, CJ1
Mallarkey, G1
Sharpe, M1
Logan, AJ1
Morris-Stiff, GJ1
Bowrey, DJ1
Jurewicz, WA1
Camara, DS1
Corasanti, JG1
Buckley, MM1
Heel, RC1
Farr, C1
Georgieff, GS1
Dotevall, G1
Holt, S1
Lamers, CB1
Dols, DM1
Gazzard, BG1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection[NCT03124199]Phase 340 participants (Actual)Interventional2014-02-28Completed
A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers[NCT01557335]Phase 130 participants (Actual)Interventional2010-11-30Completed
Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908]Phase 132 participants (Actual)Interventional2006-09-30Completed
Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555]Phase 2450 participants Interventional2006-02-28Suspended
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Compliance With Treatment of Patients That Completed the Study

Percentage of patients that has comply with treatment, considered as intake of more than 90% of study drugs in patients who attended the post-treatment visit. (NCT03124199)
Timeframe: 1 month

Interventionpercentage of participants (Number)
Rifaximin100

Percentage of Participants With H.Pylori Infection Eradication

Percentage of Participants with H.Pylori Infection Eradication confirmed with urea breath test at least 4 weeks after the end of treatment (NCT03124199)
Timeframe: 1 month

Interventionpercentage of participants (Number)
Rifaximin61

Tolerability of Treatment

Patients with side effects present during treatment and in the 4 weeks after end of treatment (NCT03124199)
Timeframe: 1 month

Interventionparticipants (Number)
with diarrheawith metallic tasteheadachenauseaabdominal pain
Rifaximin139551

Reviews

33 reviews available for omeprazole and Cholera Infantum

ArticleYear
Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:1

    Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Gastrointestinal Diseases; Gastrointestin

2017
The pharmacology of esomeprazole and its role in gastric acid related diseases.
    Expert opinion on drug metabolism & toxicology, 2009, Volume: 5, Issue:9

    Topics: Clinical Trials as Topic; Drug Interactions; Esomeprazole; Gastrointestinal Diseases; Humans; Omepra

2009
Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients.
    European journal of clinical pharmacology, 2010, Volume: 66, Issue:4

    Topics: Child; Critical Illness; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Infusions,

2010
Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole.
    Clinical drug investigation, 2012, Apr-01, Volume: 32, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Gastrointestinal Diseases; Huma

2012
Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease.
    The Keio journal of medicine, 2003, Volume: 52, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Apoptosis; Chemistry, Clinical; Clari

2003
[The treatment of Helicobacter pylori infection in upper gastrointestinal disorders].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2003, Volume: 100, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Gastritis; Gastrointes

2003
[What treatments can reduce the digestive complications of NSAIDs].
    Presse medicale (Paris, France : 1983), 2003, Nov-22, Volume: 32, Issue:37 Pt 2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Duodenal Ulcer; Gastrointestinal Diseases; Histamine H2 Ant

2003
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
    Arthritis and rheumatism, 2005, Apr-15, Volume: 53, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin

2005
Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases.
    International journal of clinical practice, 2005, Volume: 59, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Gastroesop

2005
Review article: similarities and differences among delayed-release proton-pump inhibitor formulations.
    Alimentary pharmacology & therapeutics, 2005, Volume: 22 Suppl 3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Delayed-Action Preparations; Enzyme Inhibitors; Gastrointes

2005
[Helicobacter pylori eradication therapy for children].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents

2005
Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.
    Journal of investigational allergology & clinical immunology, 2006, Volume: 16, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Benzimidazoles; Famotidine;

2006
Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases.
    World journal of gastroenterology, 2006, Jun-28, Volume: 12, Issue:24

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiova

2006
[Protonic pump inhibitors in kidney transplant patients: efficacy and safety].
    Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2007, Volume: 59, Issue:2

    Topics: Anti-Ulcer Agents; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Inhibitors; Eso

2007
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2008, Volume: 12, Issue:11

    Topics: Anti-Ulcer Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitors; Gastro

2008
[Proton pump blockers and their significance in gastroenterology].
    Vnitrni lekarstvi, 1995, Volume: 41, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas

1995
Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.
    Drugs, 1994, Volume: 48, Issue:1

    Topics: Gastric Acid; Gastrointestinal Diseases; Humans; Omeprazole

1994
Clinical pharmacokinetics of lansoprazole.
    Clinical pharmacokinetics, 1995, Volume: 28, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aging; Anti-Ulcer Agents; Drug Interactions; Gastrointestin

1995
Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders.
    Drug safety, 1994, Volume: 10, Issue:1

    Topics: Achlorhydria; Animals; Gastrointestinal Diseases; Humans; Omeprazole; Risk Factors

1994
Antiulcer therapy.
    The Veterinary clinics of North America. Small animal practice, 1993, Volume: 23, Issue:3

    Topics: Animals; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cats; Cimetidine; Dog

1993
Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Drugs, 1997, Volume: 54, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastrointestinal Diseases;

1997
Antibiotic treatment of Helicobacter pylori infection.
    Current topics in microbiology and immunology, 1999, Volume: 241

    Topics: Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Gastrointestinal Di

1999
Update on medications used to treat gastrointestinal disease in children.
    Current opinion in pediatrics, 1999, Volume: 11, Issue:5

    Topics: Anti-Bacterial Agents; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Child; Cisapride; Dru

1999
Review article: rabeprazole's profile in patients with gastrointestinal diseases.
    Alimentary pharmacology & therapeutics, 1999, Volume: 13 Suppl 5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastr

1999
Helicobacter pylori and idiopathic chronic urticaria.
    International journal of dermatology, 2000, Volume: 39, Issue:6

    Topics: Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Carbo

2000
The proton-pump inhibitors: similarities and differences.
    Clinical therapeutics, 2000, Volume: 22, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Gastr

2000
The proton-pump inhibitors: similarities and differences.
    Clinical therapeutics, 2000, Volume: 22, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Gastr

2000
The proton-pump inhibitors: similarities and differences.
    Clinical therapeutics, 2000, Volume: 22, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Gastr

2000
The proton-pump inhibitors: similarities and differences.
    Clinical therapeutics, 2000, Volume: 22, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Gastr

2000
Switching between intravenous and oral pantoprazole.
    Journal of clinical gastroenterology, 2001, Volume: 32, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Benzimidazoles; Cl

2001
[Experience in the use of losek (omeprazole) in gastroenterology].
    Terapevticheskii arkhiv, 2001, Volume: 73, Issue:7

    Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Double

2001
Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs.
    Best practice & research. Clinical gastroenterology, 2001, Volume: 15, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Gastrointestinal Diseases; Hist

2001
Lansoprazole: an update of its place in the management of acid-related disorders.
    Drugs, 2001, Volume: 61, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulce

2001
Update: gastroenterology and hepatology.
    Comprehensive therapy, 1991, Volume: 17, Issue:4

    Topics: Chronic Disease; Esophageal Diseases; Gastrointestinal Diseases; Humans; Interferons; Liver Diseases

1991
Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.
    Drugs, 1991, Volume: 42, Issue:1

    Topics: Animals; Duodenal Ulcer; Esophagitis, Peptic; Gastrointestinal Diseases; Histamine H2 Antagonists; H

1991
Omeprazole. Overview and opinion.
    Digestive diseases and sciences, 1991, Volume: 36, Issue:4

    Topics: Duodenal Ulcer; Gastroesophageal Reflux; Gastrointestinal Diseases; Humans; Omeprazole; Stomach Ulce

1991

Trials

17 trials available for omeprazole and Cholera Infantum

ArticleYear
Phytomedicine-based and Quadruple Therapies in Helicobacter pylori Infection: A Comparative, Randomized Trial.
    Alternative therapies in health and medicine, 2015, Volume: 21 Suppl 2

    Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Com

2015
Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
    American heart journal, 2013, Volume: 165, Issue:2

    Topics: Administration, Oral; Adult; Aspirin; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Dose-Res

2013
Omeprazole plus azithromycin and either amoxicillin or tinidazole for eradication of Helicobacter pylori infection.
    Journal of clinical gastroenterology, 2003, Volume: 36, Issue:4

    Topics: Adult; Aged; Amoxicillin; Azithromycin; Dose-Response Relationship, Drug; Drug Administration Schedu

2003
Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
    Alimentary pharmacology & therapeutics, 2003, Jul-01, Volume: 18, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents;

2003
Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients.
    Digestion, 2003, Volume: 68, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-

2003
[Comparative efficacy of different therapeutic schemes in gastropathies induced by nonsteroid anti-inflammatory drugs].
    Terapevticheskii arkhiv, 2004, Volume: 76, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Drug Administration Schedule;

2004
Health-related quality of life in patients with cardiovascular disease--the effect of upper gastrointestinal symptom treatment.
    Alimentary pharmacology & therapeutics, 2004, May-15, Volume: 19, Issue:10

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cardiovascular Diseases;

2004
Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery.
    Circulation journal : official journal of the Japanese Circulation Society, 2005, Volume: 69, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cardiac Surgical Procedu

2005
Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-

2006
Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report.
    Helicobacter, 1996, Volume: 1, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Clarithromycin; Diarrhea; Drug Administration

1996
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
    Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial

1998
The safety of omeprazole during pregnancy: a multicenter prospective controlled study.
    American journal of obstetrics and gynecology, 1998, Volume: 179, Issue:3 Pt 1

    Topics: Abnormalities, Drug-Induced; Adult; Birth Weight; Delivery, Obstetric; Enzyme Inhibitors; Female; Ga

1998
Enhancing compliance not a prerequisite for effective eradication of Helicobacter pylori: the HelP Study.
    The American journal of gastroenterology, 1999, Volume: 94, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy,

1999
One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases.
    Digestion, 1999, Volume: 60, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimid

1999
Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2000, Volume: 32, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance,

2000
[Comparative study of the eradication of Helicobacter pylori: ranitidine bismuth citrate versus omeprazole plus two antibiotics for seven days].
    Anales de medicina interna (Madrid, Spain : 1984), 2001, Volume: 18, Issue:7

    Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Th

2001
Upper gastrointestinal complications after renal transplantation: a 3-yr sequential study.
    Clinical transplantation, 2002, Volume: 16, Issue:3

    Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Child; Child, Preschool; Cyclosporine; Enzyme Inhibitors

2002

Other Studies

48 other studies available for omeprazole and Cholera Infantum

ArticleYear
Prospective observational study of the use of omeprazole and maropitant citrate in veterinary specialist care.
    Scientific reports, 2020, 09-25, Volume: 10, Issue:1

    Topics: Animals; Dog Diseases; Dogs; Drug Prescriptions; Gastrointestinal Diseases; Hospitalization; Omepraz

2020
Risk factors for adverse drug reactions in pediatric inpatients: A cohort study.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Anesthesia, General; Anti-Bacterial Agents; Ant

2017
First characterization of a microsporidial triosephosphate isomerase and the biochemical mechanisms of its inactivation to propose a new druggable target.
    Scientific reports, 2018, 06-05, Volume: 8, Issue:1

    Topics: Albendazole; Amino Acid Sequence; Encephalitozoon; Fungal Proteins; Gastrointestinal Diseases; Gene

2018
Changing prescription pattern of omeprazole among patients receiving clopidogrel.
    International heart journal, 2014, Volume: 55, Issue:2

    Topics: Clopidogrel; Drug Interactions; Drug Prescriptions; Drug Therapy, Combination; Follow-Up Studies; Ga

2014
The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events.
    Journal of medical economics, 2017, Volume: 20, Issue:6

    Topics: Adult; Aged; Aspirin; Budgets; Cardiovascular Diseases; Clopidogrel; Drug Combinations; Female; Gast

2017
[Topical issues of paediatric gastroenterology].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2008, Issue:1

    Topics: Child; Clarithromycin; Drug Therapy, Combination; Gastroenterology; Gastrointestinal Diseases; Helic

2008
Confounding factors for variation of clozapine plasma levels: drug interactions with proton pump inhibitor or infectious etiologies?
    European journal of clinical pharmacology, 2011, Volume: 67, Issue:5

    Topics: Antipsychotic Agents; Clozapine; Drug Interactions; Female; Gastrointestinal Diseases; Humans; Middl

2011
Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a high-prevalence area.
    British journal of biomedical science, 2010, Volume: 67, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resis

2010
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combi

2012
Low-dose aspirin: protection from the panacea.
    The American journal of gastroenterology, 2002, Volume: 97, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents;

2002
An aspirin a day keeps the cardiologist away (but what about the gastroenterologist?).
    Gastroenterology, 2003, Volume: 124, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Dru

2003
A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole.
    Alimentary pharmacology & therapeutics, 2003, Volume: 17, Issue:8

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Anti-Ulcer Agents;

2003
Lansoprazole overutilization: methods for step-down therapy.
    The American journal of managed care, 2003, Volume: 9, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Costs; Drug Utilization Review; Enz

2003
Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole.
    Scandinavian journal of gastroenterology, 2003, Volume: 38, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin;

2003
Sodium pentobarbital anesthesia transiently enhances the severity of infection following intragastric, but not intravenous, inoculation of Listeria monocytogenes in mice.
    Microbial pathogenesis, 2003, Volume: 35, Issue:2

    Topics: Anesthesia; Animals; Anti-Ulcer Agents; Antidiarrheals; Cell Culture Techniques; Cell Line; Cimetidi

2003
The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine.
    The Journal of pediatrics, 2003, Volume: 143, Issue:2

    Topics: Anti-Ulcer Agents; Child; Child, Preschool; Cysteamine; Cystinosis; Female; Gastric Acid; Gastrins;

2003
Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis.
    Rheumatology international, 2005, Volume: 25, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Cost-Benefit Anal

2005
[Gastric uptake of gallium67 in the human immunodeficiency virus infection].
    Anales de medicina interna (Madrid, Spain : 1984), 2004, Volume: 21, Issue:2

    Topics: Adult; AIDS-Related Opportunistic Infections; Aluminum Hydroxide; Anti-Bacterial Agents; Anti-Ulcer

2004
Does hormone therapy increase allergic reactions and upper gastrointestinal problems? Results from a population-based study of Swedish woman. The women's health in the Lund area (WHILA) study.
    Maturitas, 2004, Aug-20, Volume: 48, Issue:4

    Topics: Aged; Anti-Allergic Agents; Anti-Ulcer Agents; Climacteric; Cohort Studies; Female; Gastrointestinal

2004
Effectiveness of omeprazole- versus lansoprazole-based triple therapy for Helicobacter pylori eradication.
    Digestive diseases and sciences, 2005, Volume: 50, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial

2005
Protective effect of melatonin and omeprazole against alendronat-induced gastric damage.
    Digestive diseases and sciences, 2005, Volume: 50, Issue:8

    Topics: Administration, Oral; Alendronate; Animals; Anti-Ulcer Agents; Antioxidants; Fasting; Female; Gastri

2005
Gastric ulcer despite no acid in a renal allograft recipient: what is the link?
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:10

    Topics: Adult; Anti-Ulcer Agents; Cytomegalovirus; Cytomegalovirus Infections; Female; Gastric Acid; Gastroi

2005
Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy.
    Journal of gastroenterology and hepatology, 2005, Volume: 20, Issue:11

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Amoxicillin; Anti-Bacterial Agents; Anti-Ul

2005
Sporadic fundic gland polyps: clinico-pathologic features and associated diseases.
    Polish journal of pathology : official journal of the Polish Society of Pathologists, 2005, Volume: 56, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Gastric Fundus; Gast

2005
Long-term results of upper respiratory syndrome surgery and gastrointestinal tract medical treatment in 51 brachycephalic dogs.
    The Journal of small animal practice, 2006, Volume: 47, Issue:3

    Topics: Airway Obstruction; Analysis of Variance; Animals; Anti-Ulcer Agents; Cisapride; Dog Diseases; Dogs;

2006
Impact of malnutrition on gastrointestinal disorders and gross motor abilities in children with cerebral palsy.
    Brain & development, 2007, Volume: 29, Issue:1

    Topics: Adolescent; Body Mass Index; Cerebral Palsy; Child; Child Nutrition Disorders; Child, Preschool; Enz

2007
Proton pump inhibitors reduce gallbladder function.
    Surgical endoscopy, 2006, Volume: 20, Issue:9

    Topics: Adult; Enzyme Inhibitors; Female; Gallbladder; Gastrointestinal Diseases; Humans; Male; Movement; Om

2006
Acute kidney injury following proton pump inhibitor therapy.
    Kidney international, 2007, Volume: 71, Issue:6

    Topics: Anti-Ulcer Agents; Biopsy; Gastrointestinal Diseases; Humans; Kidney Glomerulus; Male; Middle Aged;

2007
Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis.
    Scandinavian journal of gastroenterology, 2008, Volume: 43, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Animals; Anti-Ulcer Agents; Antimetabolites, An

2008
Pharmacokinetics of intravenous omeprazole in children.
    European journal of clinical pharmacology, 1994, Volume: 47, Issue:2

    Topics: Adolescent; Adult; Child; Child, Preschool; Critical Illness; Esophagitis; Gastric Acidity Determina

1994
[Vision and hearing disorders with omeprazole: the facts].
    Leber, Magen, Darm, 1995, Volume: 25, Issue:1

    Topics: Blindness; Deafness; Gastrointestinal Diseases; Germany; Humans; Omeprazole; Product Surveillance, P

1995
Two-week eradication regimen for metronidazole-resistant Helicobacter pylori.
    Alimentary pharmacology & therapeutics, 1993, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Breath Tests; Ciprofloxacin; Drug Resistanc

1993
Ongoing gastric acid inhibition is a confounding factor in Helicobacter pylori diagnosis.
    European journal of gastroenterology & hepatology, 1997, Volume: 9, Issue:1

    Topics: Amoxicillin; Anti-Ulcer Agents; Biopsy; Endoscopy, Digestive System; Female; Gastric Acid; Gastric J

1997
Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database.
    BMJ (Clinical research ed.), 1998, Aug-15, Volume: 317, Issue:7156

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Prescriptions; Family Practice; Gas

1998
Gastropathy induced by nonsteroidal anti-inflammatory drugs: prescribing patterns among geriatric practitioners.
    The Journal of the American Osteopathic Association, 1999, Volume: 99, Issue:6

    Topics: Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Costs and Cost Analysis;

1999
PPI-based triple therapy in the eradication of H. pylori infection.
    Gastroenterology, 1999, Volume: 117, Issue:3

    Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Enzyme Inhibitors; Gastrointest

1999
Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.
    The New England journal of medicine, 1999, Oct-28, Volume: 341, Issue:18

    Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biological Availability;

1999
[Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases].
    Anales de medicina interna (Madrid, Spain : 1984), 2000, Volume: 17, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Cost-Benefit Anal

2000
Lactobacillus acidophilus administration added to omeprazole/amoxycillin-based double therapy in Helicobacter pylori eradication.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2000, Volume: 32, Issue:8

    Topics: Amoxicillin; Anti-Bacterial Agents; Defensins; Drug Therapy, Combination; Gastrointestinal Agents; G

2000
Coprescribing proton pump inhibitors with other medications.
    Managed care interface, 2000, Volume: 13, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Drug Interactions; Drug Prescriptions; Enzyme Inhibi

2000
Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Drugs, 2002, Volume: 62, Issue:7

    Topics: Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Gastrointestin

2002
[New special drugs registered in Austria. Losec (omeprazole)].
    Wiener klinische Wochenschrift, 1991, Volume: 103, Issue:11

    Topics: Biological Availability; Gastrointestinal Diseases; Humans; Intestinal Absorption; Kidney; Liver; Om

1991
[Drugs should never replace the art of medicine].
    Lakartidningen, 1990, Aug-29, Volume: 87, Issue:35

    Topics: Adult; Female; Gastrointestinal Diseases; Histamine H2 Antagonists; Humans; Male; Omeprazole; Psycho

1990
Omeprazole and acid inhibition: the essential issues. Proceedings of a symposium. London, April 1990.
    Digestion, 1990, Volume: 47 Suppl 1

    Topics: Animals; Gastric Acid; Gastrointestinal Diseases; Humans; Omeprazole

1990
Proceedings of the International Symposium on Omeprazole. Monte-Carlo, Monaco, 11-12 November 1988.
    Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 166

    Topics: Animals; Gastrointestinal Diseases; Humans; Omeprazole

1989
Clinical impact of H+, K+-ATP-ase inhibitors. Proceedings of a symposium. Maastricht, November 25, 1988.
    Digestion, 1989, Volume: 44 Suppl 1

    Topics: Gastrointestinal Diseases; Humans; Omeprazole

1989
The Dutch contribution to research and clinical experience with omeprazole.
    Digestion, 1989, Volume: 44 Suppl 1

    Topics: Gastrointestinal Diseases; Humans; Netherlands; Omeprazole; Research

1989
Omeprazole.
    The British journal of clinical practice, 1989, Volume: 43, Issue:11

    Topics: Animals; Dogs; Gastric Acid; Gastric Mucosa; Gastrointestinal Diseases; Humans; Omeprazole; Rats

1989